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Summary. Background: Immune responses are a major concern in gene therapy. Our previous studies demonstrated that platelet-targeted factor VIII (FVIII) (2bF8) gene therapy together with in vivo drug selection of transduced cells can rescue the bleeding diathesis and induce immune tolerance in FVIII null mice. Objective: To investigate whether non-selectable 2bF8 lentiviral vector (LV) for the induction of platelet-FVIII expression is sufficient to induce immune tolerance and how immune tolerance is induced after 2bF8LV gene therapy. Methods: Platelet-FVIII expression was introduced by 2bF8LV transduction and transplantation. FVIII assays and tail bleeding tests were used to confirm the success of platelet gene therapy. Animals were challenged with rhF8 to explore if immune tolerance was induced after gene therapy. Treg cell analysis, T-cell proliferation assay and memory B-cell-mediated ELISPOT assay were used to investigate the potential mechanisms of immune tolerance. Results: We showed that platelet-FVIII expression was sustained and the bleeding diathesis was restored in FVIII null mice after 2bF8LV gene therapy. None of the transduced recipients developed anti-FVIII inhibitory antibodies in the groups preconditioned with 660 cGy irradiation or busulfan plus ATG treatment even after rhF8 challenge. Treg cells significantly increased in 2bF8LV-transduced recipients and the immune tolerance developed was transferable. CD4 Introduction Hemophilia A (HA) is an X-chromosome-linked recessive bleeding disorder resulting from a deficiency of factor VIII (FVIII). Protein replacement therapy is effective for patients with HA, but it is burdensome, requiring repeated intravenous infusion because of the short halflife of the protein. Furthermore, up to 30% of severe HA patients will develop anti-FVIII inhibitory antibodies (inhibitors) after FVIII infusion. Using novel advanced technologies, new products have been developed with a significant increase of the protein's half-life, which may improve the quality of life for HA patients [1] . However, inhibitor development against FVIII is still a significant concern when using protein replacement therapy. Several bypassing products have been discovered and shown to improve hemostasis in HA [2] , but repeated infusions of these products have not been circumvented.
Genetic therapy offers the potential to cure disease via incorporating a functional FVIII gene into cells to achieve in vivo long-term production of therapeutic protein. Preliminary data presented at the 13th Workshop on Novel Technologies and Gene Transfer for Hemophilia from the human clinical phase I/II trial using liver-specific adeno-associated virus (AAV)-mediated FVIII gene therapy (BioMarin Pharmaceuticals, Novato, CA, USA) are very encouraging. However, patients who have severe liver disease or neutralizing antibodies to AAV, which are present in 30-50% of the population [3, 4] , are excluded from the AAV-mediated liver-targeted gene therapy protocol. Although immune responses to transgene products or viral proteins are a major concern in gene therapy protocol, they are not encountered in our platelet gene therapy protocol when transgene expression is targeted at platelets and stored in a-granules using a lentivirus-mediated gene transfer system under control of the platelet-specific aIIb promoter.
Our previous studies have demonstrated that platelettargeted FVIII gene therapy together with in vivo drug selection to enrich genetically manipulated cells (2bF8/ MGMT) not only rescues the bleeding diathesis but also induces FVIII-specific immune tolerance in FVIII null mice [5] . In the current study, we investigated (i) whether our non-selectable 2bF8 lentiviral vector (LV) for the induction of platelet-FVIII expression is sufficient to induce immune tolerance; (ii) whether preconditioning regimens affect immune tolerance induction; and (iii) how immune tolerance is induced after platelet gene therapy. We found that 2bF8LV gene delivery to hematopoietic stem cells (HSCs) without in vivo enrichment of genetically manipulated cells can introduce FVIII-specific immune tolerance in HA mice when an optimized preconditioning regimen is employed and that this immune tolerance is CD4 + T cell mediated.
Materials and methods

Mice
) mice with Foxp3GFP+ used in this study were a generous gift of Dr David Scott (Uniformed Services University of the Health Sciences, Bethesda, MD, USA) [6] . The animals were on a C57BL/6 genetic background with a targeted disruption of exon 16 of the FVIII gene [7] and a Foxp3-GFP targeted in [8] . Animals were housed in pathogen-free microisolator cages at the animal facilities operated by the Medical College of Wisconsin. Isoflurane or ketamine was used for anesthesia. Animal studies were performed according to a protocol approved by the Institutional Animal Care and Use Committee of the Medical College of Wisconsin. Both male and female animals were used in all studies.
Virus production, HSC transduction and transplantation
The pWPT-2bF8 vector, in which B-domain-deleted human FVIII expression is driven by the platelet-specific aIIb promoter, was constructed and 2bF8LV was made as described in our previous report [9] . Sca-1 + cells were isolated from FVIII null mice and transduced with 2bF8LV as previously described [9, 10] . 2bF8LV-transduced Sca-1 + cells were transplanted into 6-8-week-old FVIII null mice preconditioned with lethal 1100 cGy total body irradiation (TBI), sub-lethal 660 cGy TBI, busulfan (Bu) (50 mg kg À1 ) (DSM Pharmaceuticals Inc., Greenville, NC, USA) chemotherapy or Bu plus ATG (anti-murine thymocyte globulin, Fitzgerald, Acton, MA, USA) (10 mg kg À1 ) following the procedures described in our previous report [6] . These preconditioning regimens are optimized for platelet FVIII expression [5, 10, 11] . Animals were analyzed for 2bF8 expression, starting at 4 weeks after transplantation.
Analysis of FVIII expression in recipients
Blood samples were collected and platelets were isolated as previously described [11, 12] . Functional FVIII activity (FVIII:C) levels in recipients' platelet lysates and plasmas were quantitated using a chromogenic assay as previously described [10, 12] . 2bF8 transgene expression was determined by quantitative real-time PCR (qPCR) analysis as previously reported [9, 10] . Twelve weeks after transplantation, 2bF8LV-transduced recipients were assessed for phenotypic correction of FVIII null coagulation defect using the tail clip survival test and the tail bleeding test to grade the blood lost as previously described [5, 12] . Wild-type C57BL6 (WT), FVIII null and heterozygous 2bF8 transgenic (LV18 Tg+/-) [13] mice were used as controls in these assays.
Immune response studies
Sixteen weeks after transplantation, animals were immunized intravenously with recombinant FVIII (rhF8, Xyntha, Pfizer Inc., New York, NY, USA) at a dose of 50 U kg À1 weekly for 4 weeks. One week after the last immunization, blood samples were collected. The titers of anti-FVIII inhibitors were determined by Bethesda assay and total IgG by ELISA assay as described in our previous reports [10] [11] [12] . Some animals were subsequently immunized with ovalbumin (OVA) (Sigma, St. Louis, MO, USA) as a non-specific immunogen and the titers of anti-OVA IgG were determined by ELISA assay as previously described [14] . FVIII null mice were immunized in parallel as a control.
Flow cytometry analysis of regulatory T cells (Tregs)
Animals were euthanized and spleens were isolated. A single cell suspension of 1 9 10 6 splenocytes in 100 lL DPBS was stained with a rat anti-mouse CD4-PE monoclonal antibody (eBioscience, San Diego, CA, USA). Cells were analyzed using an LSRII Green flow cytometer (BD Biosciences, San Jose, CA, USA) for CD4-PE and Foxp3-GFP and data were analyzed with FlowJo software (FlowJo, LLC, Ashland, OR, USA).
T-cell proliferation assay
The T-cell proliferation assay was performed following the procedures described in our previous report [13] . Briefly, CD4 + T cells were isolated from rhF8-immunized FVIII null mice or rhF8-immunized 2bF8LV-transduced recipients' spleens and labeled with the cell proliferation tracer carboxyfluorescein succinimidyl ester (CFSE) (Life Technologies, Carlsbad, CA, USA). Dendritic cells from na€ ıve sex-matched FVIII null mouse spleens were used as antigen presenting cells. Cells were cultured in completed RPMI-1640 media containing rhF8 (10 U mL À1 ) or concanavalin A (ConA, a mitogen to stimulate non-specific T-cell proliferation [15] ) (Sigma) for 96 h. Cells were harvested, stained for CD4 + T cells, and analyzed by flow cytometry for CFSE expression.
Memory B cell-based ELISPOT assay
Splenocytes from either rhF8-immunized FVIII null mice or rhF8-immunized 2bF8LV-transduced recipients were used to prepare CD4 + T cells or cell pools that contained memory B cells but were depleted of antibody secreting cells (ASCs, CD138 + cells) and T cells (CD138 -T -). Memory B cell pool preparation was performed following the procedure previously reported [16] . Briefly, the splenocytes were first depleted of CD138 + cells using a rat anti-CD138 antibody (BD Biosciences) conjugated dynabeads. CD4 + T cells were then depleted from the CD138 -spleen cells using the Dynabeads Mouse Pan-T (Life Technologies). The remaining cells were used as memory B cell pools for experiments. CD4 + T cells were isolated as described in our previous report [13] . To stimulate the differentiation of memory B cells into ASCs, memory B cell pools from rhF8-primed FVIII null or rhF8-primed 2bF8LV-transduced mice were cocultured with CD4 + T cells from rhF8-immunized 2bF8LV-transduced or rhF8-immunized FVIII null mice at a cell number ratio of 1 : 1 with or without rhF8 re-stimulation for 6 days. After culture, cells were harvested and newly formed ASCs were assessed by the ELISPOT assay as described in our previous report [5] .
Adoptive transfer of splenocytes
Twenty million splenocytes from rhF8-immunized 2bF8LV-transduced recipients (the 660 cGy group) or rhF8-primed FVIII null control mice were transferred into FVIII null mice by intravenous injection without preconditioning. Twenty-four hours after transfer, animals were immunized with rhF8 at 50 U kg À1 weekly for 4 weeks.
One week after the last immunization, blood samples were collected and inhibitor titers were determined by the Bethesda assay.
Statistical analysis
Data are presented as the mean AE SEM (standard error of the mean). Statistical comparisons of experimental groups were evaluated by two-tailed Student's t-test if data distribution passed the normality test using SigmaPlot 13.0 (Systat Software, Inc., San Jose, CA, USA). The Mann-Whitney rank sum test was used for comparison if data distribution failed the normality test. A value of P < 0.05 was considered statistically significant.
Results
Successful gene therapy is achieved in 2bF8LV-transduced FVIII null mice
To determine the levels of FVIII expression in transduced recipients, we used a chromogenic assay to measure functional FVIII activity in platelet lysates at different timepoints after transplantation. Data from at least three time-points were averaged to represent the level of platelet-FVIII expression for each animal. As shown in Fig. 1 (A), under various preconditioning regimens, all animals that received 2bF8LV-transduced HSCs expressed functional FVIII in their platelets. The levels of platelet-FVIII expression in 2bF8LV-transduced recipients were 2.63 AE 1.34, 5.71 AE 1.67, 2.86 AE 0.89 and 3.04 AE 1.20 mU per 10 8 platelets in the 1100 cGy, 660 cGy, Bu and Bu+ATG groups, respectively. There was no significant difference in platelet-FVIII expression levels among these groups. No FVIII was detected in the plasma of 2bF8LV-transduced recipients. We used qPCR to determine the copy number of 2bF8 proviral DNA. As shown in Fig. 1(B) , there is no statistically significant difference among these groups although the copy number of 2bF8 in the busulfan group appears lower than that in the other groups. When the copy number of 2bF8 provirus DNA in 2bF8LV-transduced mice was compared with LV18 Tg+/À mice, which have one copy of the 2bF8 cassette per cell, the Bu group was the only group that had a significantly lower copy number of 2bF8 proviral DNA than the LV18 Tg+/À group. To assess whether bleeding diathesis was rescued in treated animals after receiving 2bF8LV-transduced HSCs, we used the tail clipping survival and the tail bleeding tests. As shown in Fig. 2 (A), all animals that received 2bF8 gene therapy survived beyond 24 h after tail-tip snipping regardless of which preconditioning regimen was employed. In contrast, none of the control untreated FVIII null mice survived under the same challenge. When a tail bleeding test was used to grade the blood lost after a 6-h tail clipping, the clotting time was 3.2 AE 0.5 h (Fig. 2Bi) and 59.4 AE 3.8% hemoglobin remained in the 2bF8LV-transduced group, which was not significantly different compared with the WT control, but significantly higher than the FVIII null control (Fig. 2Bii) . These data demonstrated that hemostasis in FVIII null mice was restored after 2bF8 gene therapy. Interestingly, although none of the untreated FVIII null control mice survived beyond 24 h in the tail survival test, all animals (n = 13) from this exon 16 gene-disrupted FVIII null colony survived beyond 6 h after tail clipping. This was significantly different from that observed in the exon 17-disrupted FVIII null colony, in which seven of 12 mice died within 6 h after tail clipping, as shown in our previous report [5] , indicating that bleeding phenotype in the exon 17 FVIII null colony may be more severe than in the exon 16 colony.
Altogether, these results demonstrate that 2bF8 lentiviral gene delivery to HSCs successfully introduced therapeutic levels of platelet-FVIII expression in FVIII null mice.
Antigen-specific immune tolerance is established in 2bF8LV-transduced recipients
To investigate whether immune tolerance is induced in FVIII null mice after 2bF8 gene therapy, anti-FVIII inhibitor titers were monitored by Bethesda assay after transplantation. As shown in Fig. 3(Ai-ii) , none of the animals developed detectable anti-FVIII inhibitors after 2bF8 gene therapy under various preconditioning regimens, whether a myeloablative 1100 cGy TBI or a non-myeloablative regimen of 660 cGy, Bu or Bu+ATG was employed. When the animals were further challenged with exogenous rhF8, none of the 2bF8LV-transduced recipients developed inhibitors when they were preconditioned with 660 cGy TBI or Bu+ATG treatment (Fig. 3B) . One of four mice developed inhibitors in the 1100 cGy group with a titer of 3.8 BU mL
À1
. Two of five mice developed inhibitors in the busulfan group with titers of 2.6 and 6.3 BU mL
. All control mice developed various titers of inhibitors after rhF8 immunization, with an average titer of 152.6 AE 48.8 BU mL À1 (Fig. 3A,B) . The anti-FVIII total IgG titers are shown in Fig. 3(C) . Before immunization, the total IgG titers in the transduced recipients under various preconditioning regimens were not significantly different compared with the FVIII null controls. After rhF8 challenge, the titers in the 660 cGy and the Bu + ATG groups were similar to the unimmunized FVIII null controls, but two of three animals in the 1100 cGy and one of four in the Bu group developed comparable titers to the FVIII null mice after rhF8 immunization.
To ensure that the immune system in 2bF8LV-transduced FVIII null recipients functions normally, some animals from the 660 cGy group were challenged with an unrelated antigen, OVA, and the titers of anti-OVA total IgG were determined by ELISA assay. The baseline of anti-OVA IgG titers was 250 AE 94 in the 2bF8LV-transduced group and 160 AE 80 in the FVIII null control group. Both 2bF8LV-transduced recipients and FVIII null control mice developed high titers of anti-OVA antibodies after OVA immunization. The titers in 2bF8LV-transduced recipients were not significantly different from those in FVIII null controls (Fig. 3D ). To investigate whether the immune tolerance developed in 2bF8LV-transduced recipients is transferable, we transferred splenocytes from recipients that had developed ) with a known single copy of the 2bF8 transgene per cell were used as a positive control and FVIII null mice were used as a negative control.
FVIII-specific immune tolerance into na€ ıve FVIII null mice, followed by four doses of rhF8 immunization. As shown in Fig. 3(E) , after rhF8 immunization, only three of 12 mice that received splenocytes from 2bF8LV-transduced recipients developed inhibitors with titers of 2.2, 3.7 and 37 BU mL À1 . In contrast, all animals that received splenocytes from rhF8-immunized untransduced FVIII null control mice developed inhibitors with titers ranging from 50 to 10 000 BU mL À1 . After rhF8 immunization, both the incidence of inhibitor development and the inhibitor titers in the group that received splenocytes from 2bF8LV-transduced recipients were significantly lower than those obtained from the group that received splenocytes from rhF8-immunized untransduced controls.
Collectively, these data demonstrate that 2bF8 lentiviral gene delivery to HSCs can establish FVIII-specific immune tolerance in FVIII null recipients when a sufficient preconditioning regimen is employed and that this immune tolerance is transferable.
Treg percentage and number increase in 2bF8LV-transduced recipients
Because Tregs play important roles in modulating immune tolerance, we analyzed Tregs in 2bF8LV-transduced recipients by FACS (Fig. 4A) . The percentage of CD4 +
Foxp3
GFP+ Tregs in spleen was 11.3 AE 0.4% in 2bF8 LV-transduced recipients preconditioned with 660 cGy TBI, which was similar to the group preconditioned with Bu+ATG. The percentage of Tregs in both groups of transduced recipients was significantly higher than in the untransduced controls (8.4 AE 0.3%) (Fig. 4B) .
The total Treg cell number in spleen was 1.39 AE 0.09 9 10 6 in 2bF8LV-transduced recipients preconditioned with 660 cGy TBI, which was not significantly different from that in the Bu+ATG group. The total number of Tregs in both groups of transduced recipients was significantly higher than in the FVIII null controls (0.79 AE 0.09 9 10 6 ) ( Fig. 4C) .
We then explored if rhF8 immunization would affect the percentage or total number of Treg cells. As shown in Fig. 4(D-E) , rhF8 immunization changed neither the percentage of Foxp3 GFP+ in CD4 + cells nor the total Treg cell number in either 2bF8LV-transduced recipients or FVIII null controls. Both the percentage and the total number of Tregs in spleen from 2bF8LV-transduced recipients were significantly higher than those obtained from the FVIII null controls both with and without rhF8 immunization. We also analyzed Tregs at various timepoints (1-4 weeks) after the last rhF8 immunization and found that there was no significant difference among these time-points (data not shown). Taken together, our data demonstrate that Tregs are increased in 2bF8LV-transduced recipients in both percentage and total number in spleen compared with untreated FVIII null mice. Because the anti-FVIII immune response is a CD4 + T cell-dependent humoral response, we used the CD4 + Tcell proliferation and the memory B cell-mediated ELI-SPOT assays to determine which cell compartment is tolerized to FVIII in 2bF8LV-transduced recipients. As 
(A) Tail clip survival test (a 24-h test)
. A minor tail-tip wound was induced by tail clipping using a 1.6-mm diameter template and the percentage of animals that survived beyond 24 h was determined. (B) Tail bleeding test (a 6-h test). Tail-tip clipping was performed using a 1.6-mm diameter template and tail bleeding time was monitored hourly and the clotting time was recorded. If tail wound bleeding did not clot within 6 h, the wounded tail tip was cauterized and the bleeding time was recorded as 6 h. Fifty microliters of blood was collected before and after the test and hemoglobin (Hb) levels were measured and normalized to the pretest level. (Bi) Bleeding time.
(Bii) Normalized Hb levels. 2bF8LV-transduced recipients subjected to the tail bleeding test were from the 660 cGy group. Factor VIII null and wild-type mice were used as controls.
shown in Fig. 5(A,B) , CFSE-labeled CD4 + T cells from rhF8-immunized 2bF8LV-transduced recipients did not respond to rhF8 re-stimulation. The percentage of CFSElabeled daughter CD4 + T cells from 2bF8LV-transduced recipients' spleens was 5.3 AE 0.7% without rhF8 re-stimulation and 5.8 AE 1.0% with rhF8 re-stimulation. In contrast, CD4 + T cells from rhF8-immunized untransduced FVIII null mice did respond to rhF8 re-stimulation. The percentage of CFSE-labeled daughter CD4 + T cells was 12.1 AE 2.6% when they were re-stimulated with 10 U mL À1 rhF8, which was significantly higher than without rhF8 re-stimulation (5.0 AE 0.4%, P < 0.01).
We then explored whether the B-cell compartment was tolerized to FVIII after 2bF8LV gene therapy. It is known that FVIII-specific memory B-cell differentiation into anti-FVIII ASCs is CD4 + T cell dependent [16] . We isolated CD4 + T cells and memory B-cell pools from rhF8-immunized 2bF8LV-transduced recipients and rhF8-immunized untransduced FVIII null controls and cocultured them with rhF8 to induce differentiation of memory B cells into anti-FVIII ASCs, which were detected by ELISPOT assay. Cocultures without rhF8 served as controls. As shown in Fig. 6(A,B) , after 6 days of stimulation with 0.2 U mL À1 of rhF8, there were 195 spots detected per 10 6 splenocytes when The anti-FVIII total IgG titers. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. (D) Anti-OVA total IgG titers. (E) The inhibitor titers in splenocyte adoptive transfer recipients after rhF8 immunization. The splenocytes were from either rhF8-immunized 2bF8LV-transduced recipients or rhF8-immunized FVIII null mice. both memory B and CD4 + T cells were from rhF8-primed FVIII null mice. However, when memory B cells from rhF8-primed FVIII null mice were cocultured with CD4 + T cells from 2bF8LV-tansduced recipients, ASCs were barely detectable after rhF8 re-stimulation. Interestingly, when memory B cells from rhF8-primed 2bF8LV-transduced recipients were cocultured with CD4 + T cells from rhF8-primed FVIII null mice in the presence of rhF8, ASCs were detectable with a frequency of 141 dots (ASCs) per 10 6 splenocytes in the presence of 0.2 U mL À1 of rhF8, although the spots were smaller compared with those obtained from the control group, in which both memory B and T cells were from rhF8-primed FVIII null mice. Together, these data demonstrate that the CD4 + T-cell compartment was tolerized to rhF8 stimulation in 2bF8LV-transduced recipients.
Discussion
Introducing a therapeutic protein via genetic therapy is an attractive strategy for hemophilia treatment, but immune responses to the transgene product or viral vector can occur when using such approaches [17] [18] [19] [20] [21] [22] [23] [24] . Immune responses may dampen the efficacy, resulting in the failure of gene therapy. To prevent an adverse immune response, immune modulation strategies using drugs or genetic manipulation have been explored in animal models [22, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . A protocol that can not only introduce sustained therapeutic levels of FVIII protein, but also induce specific immune tolerance of FVIII to prevent or reverse inhibitor formation, is desired. In the current study, we demonstrate that utilizing 2bF8LV can introduce sufficient levels of platelet-FVIII expression to restore hemostasis and to induce FVIII-specific immune tolerance in FVIII null mice. We found that immune tolerance induced by 2bF8 gene therapy is CD4 + T-cell compartment mediated and that the preconditioning regimen may impact the efficacy of immune tolerance induction in 2bF8 gene therapy.
HSCs are the promising target cells for gene therapy in many diseases because of their unique capacities, including self-renewal and differentiation into all blood lineages, providing ongoing hematopoiesis throughout the lifetime of an individual [35] [36] [37] . Expression of FVIII in hematopoietic cells has recently shown promise for treating HA with genetic therapy [17, [38] [39] [40] [41] , but low FVIII expression or the generation of FVIII inhibitors in vivo is still a problem, especially when employing clinically relevant non-myeloablative conditioning regimens [17, 38, 42, 43] . Nevertheless, targeting FVIII transgene expression to HSCs under the control of a non-specific viral promoter has induced immune tolerance to FVIII when using an effective conditioning regimen, even though sustained transgene expression has been difficult to achieve [17, 19, 44] . In our model, we use lentivirusmediated platelet-specific aIIb promoter-directed gene delivery to HSCs via in vitro transduction followed by syngeneic transplantation. Our results demonstrate that sustained FVIII expression was achieved, resulting in both phenotypic correction and FVIII-specific immune tolerance in FVIII null mice after 2bF8LV gene therapy when employing a sufficient preconditioning regimen. There were no statistically significant differences in FVIII expression levels among various preconditioning groups of lethal 1100 cGy TBI, sub-lethal 660 cGy TBI, busulfan chemotherapy and Bu + ATG treatment. All the preconditioning regimens used in the current studies were already optimized for platelet-FVIII expression [5, 10, 11] . The important question that we wanted to address in this study was whether different preconditioning regimens that result in similar expression levels of platelet-FVIII would affect the efficacy of immune responses or immune tolerance induction in platelet gene therapy.
In terms of immune responses, none of the transduced recipients developed inhibitors after 2bF8 gene therapy and no inhibitors were detected in the 660 cGy group or the busulfan plus ATG group, even after exogenous rhF8 challenge. In contrast, 25% and 40% of recipients developed inhibitors in the 1100 cGy and the busulfan groups, respectively, after rhF8 immunization. Our previous study demonstrated that busulfan conditioning alone is sufficient for achieving sustained therapeutic levels of platelet-FVIII in FVIII null mice after 2bF8LV gene therapy in the non-inhibitor model, but additional immune suppression is required for the inhibitor model [10] . Our current studies show that the addition of the immunosuppressive agent, ATG, can improve the efficacy of immune tolerance induction in 2bF8LV gene therapy. It is known that busulfan conditioning suppresses predominately the myeloid lineage and B cells, and less so the T cells [45] . Our previous study demonstrated that preconditioning is required for immune tolerance induction through infusion of platelets containing FVIII [13] . Thus, we postulate that reconstructing and educating the immune system after transplantation could be one important factor in immune tolerance induction in platelet gene therapy. Although we do not know the exact reason why 660 cGy was more successful at inducing immune tolerance, we speculate that 1100 cGy may have greater toxicities associated with TBI, which might be less optimal for immune tolerance induction. It is known that TBI can affect immune cells in the intestine [46] , which is becoming a major area for studying the immune response and immune tolerance. 1100 cGy TBI might just cause too much damage to the gut; the niche for immunomodulating cells, such as Treg cells, could have been damaged. How the conditioning regimen affects immune tolerance induction in platelet gene therapy is still unclear and warrants further investigation.
Our studies show that immune tolerance induced after 2bF8LV gene therapy is FVIII specific and transferable through adoptive transfer of splenocytes, indicating that the spleen contains immunomodulator(s) that can suppress FVIII immune responses. It is well known that Tregs play crucial roles in maintaining dominant immune tolerance [47] [48] [49] [50] [51] [52] [53] [54] [55] . The importance of Tregs in maintaining tolerance in HA mice after immune modulation or gene therapy has been reported [26] [27] [28] 31, 33, 54] . Recent studies by Kim et al. [56] show that engineered FVIII-specific Tregs from HA patients can suppress FVIII-specific T and B-cell immune responses. To explore if Tregs are involved in immune tolerance after 2bF8 gene therapy, we analyzed Treg cells in FVIII null mice after 2bF8 gene therapy. We found that both percentage and total number of Tregs in spleen significantly increased in the animals after 2bF8 gene therapy compared with untransduced controls, supporting the notion of Tregs' roles in maintaining immune tolerance.
Immune tolerance induction can occur in the T or B, or both, cell compartments. Our studies demonstrate that CD4 + T cells from FVIII-immunized 2bF8 LV-transduced recipients did not respond to rhF8 re-stimulation in vitro and failed to help rhF8-primed memory B cells differentiation into plasma cells to produce anti-FVIII antibodies. However, memory B cells from rhF8-immunized 2bF8LV-transduced recipients can differentiate into plasma cells and produce anti-FVIII antibodies when cocultured with CD4 + T cells from rhF8-primed untransduced FVIII null mice, suggesting that memory B cells in animals after 2bF8LV gene therapy are functional. Thus, we conclude that the immune tolerance induced after platelet-specific FVIII gene therapy occurs in the T-cell compartment. Whether conventional CD4 T cells themselves become anergic, and thus FVIII unresponsive, or the increased frequency of Tregs suppresses the function of FVIII-specific conventional CD4 T cells remains to be determined.
In summary, our data demonstrate that using nonselectable 2bF8 lentiviral gene delivery to HSCs can not only rescue bleeding diathesis but also induce FVIII-specific immune tolerance in HA mice even under non-myeloablative preconditioning. Attaining immune tolerance through platelet-targeted gene transfer may require an optimal preconditioning compared with achieving sustained platelet-FVIII expression alone. The immune tolerance developed after 2bF8LV gene therapy occurs in the T-cell compartment. Together, our studies show that 2bF8LV gene therapy is a promising protocol for HA gene therapy.
